CAP REPORT NUMBER 9 Drugs and the Third World

Item

Title
CAP
REPORT
NUMBER 9
Drugs and the Third World
extracted text
CAP
REPORT
NUMBER 9

Drugs and the Third World:

Chloroform
Sale and Hazards
— a Malaysian Study

CONSUMERS' ASSOCIATION OF PENANG

Drugs and the Third World:

Chloroform
Sale and Hazards
— a Malaysian Study

CONSUMERS' ASSOCIATION OF PENANG

Published by
Consumers1 Association of Penang
87 Cantonment Road,

Penang, Malaysia.

The Consumers’ Association of Penang is a voluntary

non-profit organisation which fights for the rights
and interests of all consumers through research,
educational and representational activities.

Printed by

Sun Printers Sdn Bhd
78 Church Street,

Penang, Malaysia.

Copyright (c) Consumers’ Association of Penang 1986

ISBN 967-9950-24-7

CONTENTS

3

Preface

Chapter

1

Introduction

Chapter

9

2

Chloroform: INN (International Non-

11

proprietary Name Selected by WHO)
(1)

Actions

(2)

Adverse Drug Reactions

(3)

Potential Carcinogenicity of Chloroform

(4)

Chloroform in Cough Mixtures

Chapter

3

Regulations Concerning Chloroform Worldwide

Chapter

4

Drug Information and Brands Sold in Malaysia
(1)

Information in DIMS

(2)

Warnings and Contraindications:

Inadequate Information
(3)

Indications Given

(4)

Chloroform Preparations not Listed in DIMS

(a)

Dosage instructions for Woods’ Great

Peppermint Cure
(b)

17

Dosage instructions for Boon’s Cough
Remedy

22

(c)

Dosage instructions for Breacol Cough

Syrup

Chapter

5

Advertising and Promotion of Chloroform

^9

Preparations in Malaysia
(1)

Advertisements

(2)

Package Inserts

Chapter 6
Chloroform as an Occupational Hazard

47

(1) Case Report I
(2) Case Report II

(3)

Discussion of the Above Findings

Chapter 7
Conclusion

References
Appendix 1

52

54
Dosage Instructions for Woods’ Great

56

Peppermint Cure

Appendix 2

Dosage Instructions for Boon’s Cough Remedy

57

Appendix 3

Dosage Instructions for Breacol Cough Syrup

58

Appendix 4

Package Insert for Kwan Loong Medicated Oil

59

Appendix 5

Package Insert for Tiger Oil

60

Appendix 6

Package Insert for Gold Fish Medicated Oil

61

PREFACE

Chloroform is a highly potent and dangerous anaesthetic.
It is known to cause severe liver damage and may even
cause cancer. According to Vickers’ Drugs in Anaesthetic

Practice, ’The major disadvantage of chloroform is its

effect on the liver, as severe liver damage can follow
short exposures’

(Vickers, et al, 1979: 140).

Despite all the documented evidence of its dangers, chlo­

roform is present as a component in many products market­
ed in Malaysia.

Under the Malaysian Poisons Ordinance 1952 and the Poisons
List 1983, chloroform in strengths of 10% and above is

listed as a Group C Poison. This means that it cannot be

sold or supplied by retail to any person. It can only be
dispensed by a medical practitioner on prescription.

For strengths of below 10%, however, chloroform is exempt
from the above restriction. As a result, many products on

sale in Malaysia contain chloroform. Among the products

are cough medicines, which are used by both children and
adults.

In a number of other countries, the use and sale of chlo­

3

roform have been totally banned or severely restricted.

Some of these countries are Belgium, Canada, the Federal
Republic of Germany, Italy, Japan, New Zealand, Norway,
the Philippines and Saudi Arabia.

In the US, claims about the usefulness of chloroform in

cough mixtures have been refuted. A 1973 editorial in the

Journal of the American Medical Association stated that
’there is a paucity of experimental evidence to support
the claims made for the expectorant constituents of cough

mixtures. Sodium citrate, citric acid, chloroform ... do
not increase sputum volume, render mucous less viscous,

or otherwise change bronchial secretions when administered

in the doses present in antitussive (cough) mixtures’.

In the same year, a National Academy of Sciences National
Research Council Committee reviewing the efficacy of cough

medicines found that Benylin, a very popular chloroform­

containing cough medicine in the US by Parke Davis, was
’ineffective’ (Federal Register 9 Feb 1973). Parke Davis

has now removed chloroform from Benylin.

On 30 December 1975, Dr Sidney M Wolfe of the US Health

Research Group wrote to the Commissioner of the US FDA,

urging for the ban of chloroform in all products. Dr Wolfe
said that ’in terms of efficaciousness, there is no justi­

fication for chloroform to be included in cough medicines’
and ’since there is no evidence that the presence of

chloroform in cough syrups offers any benefits, its elimi­

4

nation from the products does not require replacement by
another chemical’ (Ibid).

The fact that the use of chloroform is still allowed in
Malaysia shows a clear need for more adequate health

regulations in this country. The laxity in health regula­

tions has given free rein to pharmaceutical companies
in the promotion and advertising of their products, many
of which are aimed specifically at children.

The companies do not provide complete or clear instructions

for the use of their products, nor any warning about the
dangers of chloroform. Moreover, they tend to exaggerate
the efficacy of their products, recommending them for a

large number of ailments ranging from coughs and colds to

rheumatism.
In Malaysia, doctors and pharmacists get information on

chloroform and drug preparations containing chloroform
from three main sources:



the Drug Index for Malaysia and Singapore (DIMS) , which

is given free to doctors



drug advertisements and brochures, distributed free to

doctors by sales representatives of the drug companies



drug inserts, packages and labels, which come together

with the products purchased

It should be noted that all the above sources are prepared

by the pharmaceutical companies. Therefore, there is a

5

possibility that doctors are prescribing drug prepara­
tions containing chloroform to their patients without
realising the possible adverse side effects that could

arise.
What is definite is that many consumers themselves are

purchasing chloroform-containing products over the counter

in drugstores, supermarkets, etc. and using them without
being aware of the dangers of chloroform.
Experiments with animals have shown that chloroform is a

potential carcinogen. This was confirmed by a study done

by the US National Cancer Institute. Based on such evidence
the US FDA in 1976 announced its intention to prohibit the

use of chloroform as an ingredient in drugs and cosmetic
products and as a food additive.
The FDA stated that ’a clear demonstration that a compound
is carcinogenic in experimental animals must be taken as
evidence that it has the potential for carcinogenesis in

humans ...’ (WHO DIB October 1976: 13).

Pharmaceutical manufacturers were then given notice to

remove chloroform from all products, including traditional

cough preparations, liniments and toothpastes, as soon as

possible (Ibid).
Chloroform has also proved to be an occupational hazard,

as revealed in a report in the Medical Journal of Malaysia

6

Vol 38 No 1 March 1983. According to the report, what was

originally suspected to be an outbreak of viral hepatitis
among workers in two factories in Singapore was later
diagnosed as an outbreak of toxic hepatitis, the result

of chemical exposure to chloroform.
All the facts presented in this report show that the use

of chloroform in products like drug preparations should

not be allowed at all. As stated by Vickers, ’Because of
the danger of liver damage, and in spite of its cheapness,

acceptable odour, non-inflammability and useful anaesthetic

properties, there appears to be no indications for the
use of chloroform when safer and equally effective agents

are available’ (Vickers, et al, 1979: 140).
CAP therefore strongly urges the Ministry of Health to act

immediately to ban the use of chloroform in all products,
so as to ensure the good health of all Malaysian consumers,
including children.

I would like to thank Evelyne Hong and Shila Rani Ranjit
Kaur for the research and the writing of this report.

S M Mohd Idris, JP
President

Consumers’ Association of Penang

1986

7

CHAPTER 1

INTRODUCTION

Chloroform has acquired a fearsome reputation as a high­

ly potent and highly dangerous anaesthetic with a liabi­

lity to cause death due to vagal (pertaining to the vagus

nerve) cardiac arrest and to ventricular fibrillation
(convulsive movements of the ventricles of the heart)

while it is being administered. Much of this reputation

could be ascribed to the uncontrolled administration of
excessive inhaled concentration of chloroform to unpre­

pared, hypoxic (suffering from a deficiency of oxygen in
inhaled air) and hypercarbic (having excessive carbon

dioxide in the blood) patients. Chloroform has more cardiac

irritant properties than most other inhalation agents. It
is a respiratory depressant (a medicine which reduces

respiratory activity and the vital energies in general

by producing muscular relaxation) (Vickers, et al, 1979:

140) .

The major disadvantage of chloroform is its effect on the

liver; severe liver damage can follow short exposures to
the compound. In so-called delayed chloroform poisoning the

effects of chloroform appear 24-48 hours after administra­

tion. There is centrilobular necrosis (death of the central

9

portion of a lobule of the liver), which in severe cases
may become massive. This form of liver damage is said to

be more likely to occur in starved, dehydrated and toxic

patients or in those repeatedly exposed to chloroform
(Ibid).

This report by the Consumers’ Association of Penang

urges the Ministry of Health to immediately review the
benefit of this compound, bearing in mind the deleterious

effects of the compound and hence its toxicity, and to

impose a ban on its use in products. At present chloroform
in strengths of 10% and above is listed as a Group C Poison

which means that it cannot be sold or supplied by retail to
any person. It can only be dispensed by a medical practi­

tioner on prescription. However there is no restriction on
the use of chloroform in strengths of below 0.25%. And in

strengths of 0.25-9.99%, chloroform is listed as a Group E

Poison, with retail sale restricted to licensed pharmacists
and labelling requirements only. This lax Malaysian health

regulation has given rise to a situation where many prepa­
rations containing chloroform can be purchased over the

counter, which should not be the case because of the toxi­
city of the compound.

10

CHAPTER 2

CHLOROFORM: INN (International Nonproprietary Name

Selected By WHO)

(1)

Actions

Chloroform has a characteristic odour and a sweet burning
taste (Martindale 28th ed: 693). It is a potent anaesthetic

and possesses good analgesic and muscle relaxant properties
as well (Ibid).

Because of the danger of liver damage, and in spite of its
cheapness, acceptable odour, non-inflammability and useful
anaesthetic properties, there appears to be no indications

for the use of chloroform when safer and equally effective

agents are available (Vickers, et al, 1979: 140).

(2)

Adverse Drug Reactions

Chloroform is hepatotoxic (causing liver damage) and

nephrotoxic (causing kidney damage). It depresses respi­

ration and produces hypotension (low blood pressure)

(Martindale 28th ed: 693). It may take six to 24 hours
after a dose before appearance of delayed symptoms charac­

terised by abdominal pain, vomiting, and at a later stage,

11

jaundice (Ibid).
In mice, chloroform produces liver damage in both sexes.

It was found that chloroform did not develop renal tribular
necrosis (death of cellular material or of a section of

tissue due to irreversible injury to nuclear structure) in

female and castrated male mice (Ahmadizadeh, et al, 1984:
161-72).

Results of several experiments with mice have suggested

that the incidence and severity of the nephrotoxicity
caused by chloroform varies according to the species,

strain and sex of each animal (Pohl, et al, 1984 Vol 12

No 3: 304-8).
(3)

Potential Carcinogenicity of Chloroform

The earliest evidence which suggested that chloroform was

cancer-causing was found in experiments conducted by
Eschenbrenner and Miller in 1945. They discovered that

liver tumours were found in animals given 30 oral doses
of a chloroform-containing solution (Eschenbrenner, et *al,

1945 Vol 5: 251-5). A few years later, as a result of a
series of experiments using small numbers of animals,

another researcher also suggested the liver tumour­
producing properties of chloroform (UICC Monograph Series
1967, Vol 7: 135).
In 1972, the International Agency for Research on Cancer

12

(IARC) in Lyon, in a review of the question of chloroform

carcinogenicity, stated that: ’The carcinogenicity of
chloroform has been investigated only in mice ... Never­

theless, among these the frequency of liver tumours was
high ...’ (IARC Monographs 1972 Vol 1: 61-5).
Shortly after this review, the US National Cancer Institute

(NCI) initiated a feeding study of the carcinogenicity of
chloroform in mice and in rats (Public Citizen 30 Dec 1975).

On 19 November 1975, at a meeting of the US Environmental

Protection Agency (EPA), Hazardous Materials Advisory
Committee, it was stated that ’the NCI Study has confirmed
the carcinogenicity of chloroform’ (Ibid). The NCI study

found tumours in both mice and rats, with liver cancer

in mice and kidney tumours in rats (National Cancer
Institute 1976). While chloroform has long been known to
cause liver damage, this study has now confirmed the long-

held suspicion that the drug can also cause cancer (Ibid).
On 9 April 1976, the US Food and Drug Administration (FDA)

gave notice in the Federal Register of its intention to

prohibit the use of chloroform as an ingredient in drugs
and cosmetic products and as a food additive. The FDA in
formulating its decision stated that ’a clear demonstration

that a compound is carcinogenic in experimental animals
must be taken as evidence that it has the. potential for.

carcinogenesis in humans unless there is strong evidence

to the contrary (WHO DIB October 1976: 13). Pharmaceutical
13

manufacturers were given notice to remove chloroform from
all products, including traditional cough preparations,
liniments and toothpastes, as soon as possible (Ibid).

In mice and rats, chloroform has also been found to be
teratogenic (causing birth defects). However it is because

of the carcinogenicity (ability to cause cancer) of the
compound that its use in pharmacy has been recommended

to be discontinued and the maximum permissible level of

industrial exposure has been drastically lowered to 10 mg/
3
m of inhaled air (National Institute for Occupational
Safety and Health).

An average man under conditions of moderate exertion will
3
breathe m about 10m of air in an eight-hour working day.

At the maximum recommended level of exposure given above,

the total amount of chloroform to which his body would be
exposed via inhalation would be 100 mg per day although
not all of this would necessarily be absorbed (Ibid).

(4)

Chloroform in Cough Mixtures

Chloroform is commonly used as an ingredient in cough

mixtures. It is claimed that the compound increases
sputum volume and renders mucous less viscous (sticky).

However, according to a 1973 editorial in the Journal of

the American Medical Association, ’there is a paucity of
experimental evidence to support the claims made for the
14

expectorant constituents of cough mixtures. Sodium citrate,
citric acid, chloroform ... do not increase sputum volume,

render mucous less viscous, or otherwise change bronchial
secretions when administered in the doses present in anti-

tussive (cough) mixtures’ {Journal of the American Medical

Association 1973 Vol 224: 621).
In the same year, a National Academy of Sciences National

Research Council Committee reviewing the efficacy of
cough medicines found that Benylin, a very popular cough
medicine in the US by Parke Davis, was ’ineffective’, that

is, it lacked any evidence of efficacy {Federal Register
9 Feb 1973). Parke Davis has now removed chloroform as an

ingredient in Benylin.

In his letter on 30 December 1975 to the Commissioner of
the US FDA urging for the ban of chloroform in all products,

Dr Sidney M Wolfe of the US Health Research Group said that
’in terms of efficaciousness, there is no justification

for chloroform to be included in cough medicines’ and ’since
there is no evidence that the presence of chloroform in

cough syrups offers any benefits, its elimination from the

products does not require replacement by another chemical’
(Ibid).

It is recommended that persons with liver dysfunction,
alcoholics, drug addicts, pregnant women and nursing

mothers should not be exposed to even low levels of
chloroform (Ibid).

15

Chloroform is also contained in toothpaste, liniments

salves and hair-tinting preparations (Ibid) .

16

CHAPTER 3

REGULATIONS CONCERNING CHLOROFORM WORLDWIDE

Chloroform has been removed from most marketed drugs inclu­
ding cough preparations, liniments and toothpastes in the

countries listed below (Consolidated List of Products 1983).
However, many of these countries’ regulations are meant for
products entering domestic national markets; they do not

necessarily extend to products destined for eiq)ort. Hence
proprietary medicines containing chloroform which are

locally banned in some countries can still be exported

(WHO DIB Oct-Dec 1979: 6).

Canada

As of January 1978 the National Legislation has provided

that no manufacturer or importer shall sell for human use
a drug that contains chloroform as an ingredient. The
Health Protection Branch has reviewed evidence from the

National Cancer Institute in the US which suggests that

chloroform may be carcinogenic in rats and mice when
administered in high doses over prolonged periods. Export
of this product is allowed with no requirement of foreign

notification regarding domestic restrictions on its use.

17

Federal Republic of Germany

Here chloroform is prohibited for use and/or sale.

Denmark

Chloroform is registered only for veterinary use in
Denmark from 1981.

Dominican Republic

From 1983, domestic manufacturers and importers have been
requested to eliminate this ingredient from their marketed

products since pharmacological studies have shown it to be
toxic to the liver and the heart and to be carcinogenic.
United Kingdom

Since 1979, the Chloroform Prohibition Order has banned the

sale or supply of any medicinal product containing chloro­
form. However certain exemptions still do apply in the
United Kingdom.

Then, as from 28 March 1980, the sale or supply of any

medicinal product consisting of, or containing, chloroform
was prohibited in the United Kingdom (WHO DIB Jan-March
1979: 19). However a maximum concentration of 0.5% of
chloroform content in all formulations is still allowable
and a number of exemptions are even made for toothpaste,

18

anaesthetics, other products used in dental surgery,
medicines dispensed for specified individuals against
a prescription, and preparations intended for external

applications (Department of Health and Social Security,
UK, The Medicines (Chloroform Prohibition) Order SI 1979:
382).

Italy

As of 1978, chloroform has been withdrawn from the market
owing to suspected carcinogenicity.
Japan

In Japan, since 1976, chloroform has been banned by the
Pharmaceuticals Affairs Bureau in drugs and cosmetics for

reasons of carcinogenicity. However export of chloroform

is allowed with no requirement of foreign notification
regarding domestic restrictions on use.

Norway

As of April 1978, chloroform has been prohibited for use
in pure form or as an additive to pharmaceutical prepara­

tions in Norway.

New .Zealand
From 1980, all toothpaste formulations containing chloro-

19

form have been voluntarily withdrawn from the market in
New Zealand.

Philippines

As of April 1978, chloroform has been prohibited for use
as an ingredient in human drugs and cosmetics by Adminis­

trative Order No 34 in the Philippines.

Saudi Arabia

As of 1977, sale or supply of any medicinal product

containing chloroform has been prohibited by the Drug
Corqni tree in Saudi Arabia.

Turkey

As of 1976, chloroform has- been removed from all cough
syrups following a decision by the Ministry of Health

based on a review of published information regarding
carcinogenicity in rats. Export of this product has also

been prohibited.

Venezuela

In Venezuela, chloroform is subject to restricted use and/
or sale.

20

Belgium

The Ministry of Public Health and Family Affairs of Belgium
has withdrawn all products containing chloroform intended

for systemic use on the grounds of lack of efficacy, and

because of the carcinogenic potential and toxicity of this
substance (WHO DIB April-June 1984).

Malaysia

In contrast, the Malaysian health regulation on chloroform
is lax.

Under the Poisons Ordinance 1952 and the Poisons List 1983,
chloroform is listed as a Group C Poison for strengths of

10% and over. A Group C Poison cannot be sold or supplied

by retail to any person. It can only be dispensed by a
registered medical practitioner, registered dentist

Division I or veterinary surgeon, or by a licensed pharma­
cist, as a dispensed medicine on and in accordance with a
prescription written out by a registered medical practi­
tioner, registered dentist or veterinary surgeon.

However, there is no such restriction on chloroform in

strengths under 10%. Hence, it is present as an ingredient
in many products on the market.

21

CHAPTER 4

DRUG INFORMATION AND BRANDS SOLD IN MALAYSIA

In Malaysia, doctors and pharmacists obtain information

on chloroform from three major sources. They are:

a)

The Drug Index for Malaysia and Singapore (DIMS) .

DIMS is a quarterly publication on ethical medicines
available in Malaysia and Singapore. It is prepared

by the pharmaceutical companies and distributed free

to doctors in both countries.
b)

Drug advertisements and brochures which are distribu­
ted free to doctors by drug company retailmen.

c)

Drug inserts, packages and labels which come together
with the drugs when they are purchased. These give, or
should give, information on the use of the drugs, the

dangers and the precautions to be taken when the drug

is used. The instructions and information on the drug
are provided by the company which markets its parti­
cular brand product.

By referring to DIMS and by examining the package inserts

of the various chloroform products published by the

22

pharmaceutical industry, it was found that the information
provided was inadequate. Not enough was said about the

dangers of chloroform to children as well as adults. There
were no indications as to its toxicity and its ability to
cause liver damage.

(1)

Information in DIMS

Chloroform is not listed in the generic names register in
DIMS. Hence, not all preparations containing chloroform

can be traced. However, three preparations of ’Cough and
Cold Remedies’ containing chloroform are found in DIMS

(Vol 14 No 2, June 1985: 93-4).
They are:

* Cofnil
* Diphendryl/Diphendryl CP
* Diphenmine

Diphendryl/Diphendryl CP and Diphenmine are both Group C

Poisons.
The manufacturers of the three chloroform preparations,

together with their contents, are listed in Table 1.

23

Under the notes on Symp a th omi metics, information is

provided as follows:
1 Contra-Indications:

Idiosyncrasies to sympathomimetics ,

hyperthyroidism, hypertension and coronary disease.
Sympathomimetics should not be used concomitantly with

nor within 2 weeks of MAO Inhibitor therapy.
Special Precautions:

Caution in cardiac disease and

diabetes, and in pregnancy as uterine contractions may be

inhibited. ’
There is no single mention of chloroform and warning

against its toxicity.

(3)

Indications Given

Apart from the complete absence of information on chloro­
form, the indications for the three drugs are as follows:
COFNIL CD - Pharmmalaysia

’Indications:

C/I & S/P:

Cough suppressant

See notes 2 & 3 section 3c of DIMS, Vol 14 No
2 June 1985.’

26

DIPHENDRYL/DIPHENDRYL CP - Asia Pharm
’Indications:

Cough and upper respiratory congestion and/

or dry and irritating cough in CP.
C/I & S/P:

See notes 1 & 3 section 3c.’

DIPHENMINE - Camden

’Indications:

Control of cough and alleviation of nasal

stuffiness, sneezing, lachrymation and

bronchial congestion.

C/I & S/P:

(4)

See notes 1 section 3c.’

Chloroform Preparations not Listed in DIMS

Other cough and cold remedies and local medicines not

listed in DIMS and containing chloroform are available
over-the-counter in sundry shops, supermarkets and

medicinal halls all over the country. CAP obtained:

* Breacol Cough Syrup (Sterling)
* Woods’ Great Peppermint Cure (Woods)
* Boon’s Cough Remedy (Boon Pharmacy)
* Minyal Angin Cap Singa Kwan Loong (Hudson Malaysia Sdn Bhd)
* Tiger Oil
* Minyal Angin Cap Ikan Mas (Ban Choon Tong Sdn Bhd)
t In a market survey in September 1986, CAP noted that chloroform was no longer listed
in the contents of Woods’ cough medicine. According to a company official that CAP
contacted, Woods had removed chloroform from its cough medicine as of April 1986.
However, CAP found that some of the old preparation containing chloroform
were still on sale. In this report, study on Woods’ cough medicine is based on the
original formula.

27

Products containing chloroform, found on the market

SAIZ POCKET
ME
SAKIT ME PAIA

StlSEWA PlfAM
SAKIT PEAUT. OAH
[Alt IAIM DiSAPU
8AGI 5IMUA OAAWG
I («« Aua M«4»*

|

The products, together with their manufacturers and

contents, are listed in the table below.
Table 2:

Chloroform Preparations not Listed in DIMS
Source:

CAP survey

Brand Name

Manufacturer
1

Contents

1)

Boon’s Cough
Remedy

Boon Pharmacy

Chlorodyne
1.24
Tr. Ipecae
4.69
Tr. Scillae
2.105
Syr. Tolu
Q.S.
Inf. Senegae
Cone.
4.69
Spt.Chloroform 0.62
Aq.Chloroform add 100

2)

Woods’ Great
Peppermint
Cure

Woods

Acid Benzoic
0.46
Aether
0.14
Camph.
0.0067
Chlorof.
1.07
Glycer
0.85
01. Anis
0.0067
01. Menth. Pip 0.90
Pot. Nitras
6.54
Alcohol
5.00

3)

Breacol Cough
Syrup

Sterling

Extract White
Pine Comp.
FE Horehound
Glucose
Liquid
Menthol
Chloroform
Oil Pine Tar
Soluble
Saccharin

32

1.102 gm
0.521 ml
92.51 gm
0.068 gm
0.416 ml
0.033 ml
0.003 gm

Brand Name

Manufacturer

Contents
Caramel1.5
ml
Ammonium
Chloride
1.26 gm
Honey
4.375 ml
Oil Eucalyptus 0.13 ml
XYLOPOL, Brand
of HexylDihydroxybenzene
0.1
gm
Purified water,
q.s. ad
100
ml

4)

Minyak Angin
Cap Singa
Kwan Loong

5)

Tiger Oil

6)

Minyak Angin
Cap Ikan Mas

Hudson
Malaysia Sdn
Bhd

Menthol Crystal 25%
Camphor Powder 10%
Chloroform B.P. 0.5%
Oil Lavender
Spike
7%
Methyl
Salicylate
15%
Eucalyptus Oil 10%
32.5%
White Oil
Menthol
Methyl
Salicylate
Camphor
Eucalyptus Oil
White Oil
Lavender Spike
Chloroform

Ban Choon Tong
Sdn Bhd

33

8.00%
38.00%
17.50%
6.00%
25.00%
5.00%
0.50%

Menthol Crystal 28.5%
Methyl
Salicylate
12.0%
Chloroform
3.0%
White Oil Q.S.ad 100%
Camphor
5.1%
Eucalyptus Oil
4.7%
Lavender Oil
4.5%

Some advertisements for
chloroform products that
have appeared in local news­
papers and periodicals

Stop it with Breacol,
the family cough medicine.

Many of these preparations are widely advertised in our
local newspapers and periodicals.

They are very popular

and are used by children and adults.

Some users

interviewed by CAP said that the preparations were very

effective and cheap.
Chloroform has been proven to cause liver damage.

If

cough mixtures containing this substance continue to be

administered to children from a very tender age, the
long-term effects may prove to be fatal.

Yet the preparations CAP came across are meant for

children as well as adults.

Below are examples of

dosage instructions for children.

(a)

Dosage instructions for Woods1 Great Peppermint Cure

(See Appendix 1)
The instructions on the box are written in English, Chinese
Malay and Tamil.

The dosages for children are:

from 10 - 15 years of age, half a teaspoonful
from

5-10 years of age, fifteen drops

for

5 years and under, five drops

There are no instructions as to how often the cough mixture
should be administered to children.

The dosage for adults

is one teaspoonful four or five times a day.

35

From the formula given on the bottle label, it was
calculated that every 15ml of the cough syrup would

contain about 7% of chloroform.
concentration indeed.

This is quite a strong

Giving chloroform to children in

such high doses is extremely dangerous.

(b)

Dosage instructions for Boon's Cough Remedy
(See Appendix 2)

The instructions on the box are given in English, Chinese

and Malay.

The dosages for children are:

one dessert-spoonful for 10- to 16-year-olds
one teaspoonful

for

6- to 10-year-olds and

half a teaspoonful

for

3- to

6-year-olds

Here too, there are no instructions as to how often the

cough mixture should be administered to children.

The

dosage for adults is one tablespoonful every 3-4 hours.

(c)

Dosage instructions for Breacol Cough Syrup
(See Appendix 3)

The instructions on the box are written in English,

Chinese and Malay.

The dosages for children are:

12-year-olds

2/3 teaspoonful

8-year-olds

1/2 teaspoonful

5-year-olds

1/3 teaspoonful

Infants

5 to 10 drops every 3 or 4 hours

The dosage for adults is 1 teaspoonful every 3 or 4 hours.
36

It should be noted that all the dosage instructions are
not very clear, and in certain cases may give rise to

confusion as to how much of the preparation should be

given to a child.
When the chloroform issue was brought up in Malaysia in
November 1976, the Minister of Health at the time,
Tan Sri Lee Siok Yew, stated that The Poisons Board of his
Ministry was conducting a study to find out whether the

use of chloroform in drugs and cosmetics posed health
He added that further action on the use of the

hazards.

chemical would be taken after receiving the recommendations
of the Board.

In 1977 The Poisons Board recommended to the Ministry of
Health that the use of chloroform in preparations be

retained.

Chloroform in strengths of 10Z or over in

preparations should remain unchanged and be classified

as Part I - Group C Poisons; preparations which contain

chloroform in strengths of O.25Z - 9.99Z should be
classified as Group E Poisons and there should be no
restriction on the use of chloroform for strengths below

O.25Z.

The Board’s ’contention is that chloroform is

widely used as preservative in strengths of below O.25Z’.

The Poisons Board also added that, ’pending receipt of
a fuller report from FDA, Washington, our recommendation

can be further reviewed if necessary’.

The FDA had

removed all chloroform from pharmaceutical preparations
since 1976 (Berita Farmasi, Vol 4 No 2 Feb 1977: 27).

37

Nine years have passed since then and no action has been
forthcoming from the Health Ministry.

Products containing

chloroform, such as cough and cold mixtures, continue to be

sold in Malaysia.
The Ministry of Health must halt the drug companies’

dumping of products containing chloroform that have been

banned elsewhere.

It should also warn local manufacturers

to remove chloroform from all their products immediately.

38

CHAPTER 5
ADVERTISING AND PROMOTION OF CHLOROFORM PREPARATIONS IN
MALAYSIA

Generally, the advertisements and package inserts of the
preparations make highly exaggerated claims about the

properties and effectiveness of the products.

In many

cases, the advertisements make use of children to sell
the products, giving the idea that the products are ideal
for the whole family, including the children.
(1)

Advertisements

In March 1980, four advertisements of Kwan Loong
Medicated Oil appeared in the New Straits Times. The

product was advertised with the four virtues of
Honesty, Trust, Wisdom and Strength written in Chinese

characters.

At the end of each of the advertisements was

stated ’Honest in claims and effectiveness’, ’Trusted by
generations’, ’A product of wisdom, trusted by the wise’

and ’Strong and gentle, a friend indeed’ respectively.

The aim here is to give an air of reliability to the
product.

In December 1985, another advertisement for Kwan Loong
Medicated Oil appeared in the Star. It was advertised as

39

fr>r Kwan Loong Medicated Oil

Another advertisement for Kwan Loong Medicated Oil

The popularfavourite
that has been easing
coughs and colds
for more than 80 years.

follows: 'When it comes to you and your family's good
health, your first thought for an effective and trustworthy
medicated oil is Kwan Loong ... It is worth the price you

pay ... Good value down to the very last drop.'
The New Straits Times (31/3/81) carried an advertisement

on Woods' Great Peppermint Cure that said, in large, bold
print: 'The popular favourite that has been easing coughs

and colds for more than 80 years'.

The statement implies

that since the preparation has been available for such a

long period of time, it has to be safe and good for use.
In other words, the statement lends an air of respectability

and dependability to the product.
In October 1985, the Sarawak Tribune carried an

advertisement on Woods’ Great Peppermint Cure Children's
Cough Syrup that said: 'Just for little ones like us'.
After this was stated: 'Little ones need special care.

And Woods' know how.

Woods' Great Peppermint Cure

Children’s Cough Syrup is specially formulated for little

ones.

It's pleasant tasting.

Very soothing.

relieve coughs, even colds and sore throats.

And helps

Woods'

Children's Cough Syrup works fast and is effective.

No

wonder it's the great family solution trusted for
generations .'

Right next to these words is a picture of three smiling

children.

This is an example of an advertisement that is

aimed primarily at children.

43

Advertisement for Breacol Cough Syrup

Stop it with Breacoi,
the family cough medfcme.
Breacol fights coughs
5 ways.
1.

Contains a special ingrerkent.
XYLOPOL. that stops the action of
coughcausing germs.

2.

Cod. mentholated flavour soothes
rotation of throat and Logs.

3.

Rebeves throat tickle.

4.

Helps dear choking pheigm

5.

Eases the urge to cough.

Hus. Breacoi contains glucose to give
you energy.

Breacoi works eflectrvety for adufts. And
it s ideal for chddren too* Just make sure
you foGow dosage nstructions carefdty.
Breacoi. The proven cough medicine that
works 5 ways to provide more effective
rebef from coughs.

ideal for children and adults.

Breacol
Stops coughs 5 ways.

KXU U. 0O6OT8 J/AflOG

The advertisement for Breacol cough syrup (Borneo Bulletin,
4/2/84) shows a picture of a family - father, mother and

son - playing together happily.

The idea here is also to

convey the message that the product is suitable for the

whole family, that it takes care of the whole family’s
health and that it contributes to the family’s happiness.

This is reinforced by describing Breacol as a ’family
cough medicine’ that is ’ideal for children and adults’*
(2)

Package Inserts

The popular local liniment Kwan Loong Medicated Oil
(zninyak angin or commonly known as ’ Ipoh Oil’), which
contains 0.5% chloroform, is recommended in the insert

’for all external ailments and as a first aid in emergencies*
It is an unfailing preventive against influenza and other
contagious diseases.

Miners, planters, tourists, business­

men and athletes will find it handy and indispensable’
(See Appendix 4).

The liniment is recommended for such ailments as sprains,

rheumatism, chest complaints, sores, bruises, cuts,

toothache and fainting fits.

In the case of Tiger Oil, the information insert states

that it is ’manufactured by the most up-to-date

pharmaceutical processes.

Its production is carefully

controlled at all stages by skilled pharmacists and

45

chemists to give a product of the highest quality’ (See
Appendix 5).

Exactly what the ’up-to-date pharmaceutical processes’ are

is left to the imagination.

And the phrase ’... product

of the highest quality’ is used to imply that the product

is really good and reliable.
The product is said to be ’a time-tested and effective
household remedy’ for the symptomatic relief of headache,
stomachache, colds, coughs, giddiness, overwork, mental

tiredness, insect bites, travelling sickness and

rheumatism.

The information insert for Gold Fish Medicated Oil (See

Appendix 6) states the following: ’This Medicated Oil is
essential for everybody. It has many effective use.

A

few drops will do you miracles ... It is pleasant in

taste and entirely free from harmful substances ... and is
suitable for use by both adults and children.’

Ailments for which this product is recommended range from
influenza and sinusitis to overwork and rheumatism.

The claim that ’a few drops (of the medicated oil) will

do you miracles’ is obviously an exaggeration, typical of
the claims frequently made by the advertisements and package

inserts of the chloroform preparations on sale in Malaysia.

46

CHAPTER 6

CHLOROFORM AS AN OCCUPATIONAL HAZARD

Below are reports of complications associated with the

use of the drug, chloroform, as cited from the Medical
Journal of Malaysia (Vol 38 No 1 March 1983:31-4).
(1)

Case Report I

Between October 1973 and July 1974, 13 workers from a

large factory in Singapore were diagnosed by their
doctors as having viral hepatitis.

Except for two, all

had symptoms of anorexia (lack or loss of the appetite

for food), nausea and vomiting.

The other two who had

no symptoms had been noticed by their colleagues to be

jaundiced.

All 13 were jaundiced when seen by the doctors.

It was found that all 13 came from one section of the

factory.

Past medical histories for all were negative.

In this particular department, work was mainly mechanical,
related to the sub-assembly of electrical toasters.

No

chemical was being used except a degreasing agent on the

contact welding machines.

This agent was found to contain

99.5% chloroform and 0.5% ethyl alcohol.

47

The level of chloroform vapour in the air was found to be

more than 440ppm (upper limit of the range measurable on
detector tubes).

analysed.

Blood samples of workers were taken and

Blood chloroform levels between 0.10 and O.29mg

per 100ml were found in these workers.

(2)

Case Report II

Between May and August 1980, 11 cases of acute infectious
hepatitis were reported in another factory in Singapore.

This one produced radio cassette recorders and digital

clock radios.
No Hepatitis B surface antigen (virus causing hepatitis)

was found, showing that the factor responsible for the
outbreak could not be the hepatitis virus.

It was first thought that contaminated drink from a

vending machine was the vehicle of transmission.

However between November 1980 and October 1981, five more
cases of infectious hepatitis were reported from this
factory. Since all the cases reported came from the same

department of the factory and a chemical smell was detected
in the workroom, chemical intoxication was suspected.

The

matter was then referred to the Industrial Health Division

of the Ministry of Labour in October- 1981 for further
inves ti gation.

48

(Besides these 16 hepatitis cases reported, it was later

discovered that there had been two more cases from the

same factory.

One victim was hospitalised in May 1980

and the other in October 1980.)

The hepatitis cases were found to be from the Casing

Department.

Here there were five assembly lines where

components were assembled, encased and packed for export.
Chloroform was used as an adhesive.

It was either

squeezed out from a small plastic bottle or poured out
onto a small open dish and applied with a brush.

When

chloroform was applied to the plastic casing or to other

components, it melted the plastic.

The various components

Whenever more chloroform

could then be stuck together.

was required, it was poured from a tin containing chloroform
in one part of the room, into the dishes or small bottles

for the operators on the assembly lines.
An assessment of chloroform vapour in the air of the
workroom was made on two occasions.

On 14 December 1981,

spot tests using a portable infrared gas analyser detected
between 14.4 and 33.3 ppm of chloroform.

On 22 December

1981, gas chromatographic analysis by the Department of
Scientific Services showed levels of between 19.6 ppm

and 50.4 ppm.

The threshold limit value (TLV) of chloroform was 10 ppm
(TLV refers to that degree of concentration of a substance
in the blood plasma above which the substance is excreted

49

by the kidneys and below which it is not excreted) .

(3)

Discussion of the Above Findings

The two outbreaks of toxic jaundice described showed
similar features.

They were traced to occupational

exposure to chloroform, a known hepatotoxic agent.

In

both outbreaks, the workers affected had been exposed to

the chemical for less than six months.
All the cases were originally diagnosed as having viral
hepatitis, a common cause of jaundice.

But the diagnosis

of toxic hepatitis was made retrospectively based on

epidemiological evidence.

Occupational exposure to high

levels of chloroform vapour was confirmed.
The signs and symptoms of toxic hepatitis from chloroform
exposure were similar to those of viral hepatitis.

The

latter condition is often a presumptive diagnosis made on
clinical grounds, especially for type A disease, although

a positive test for hepatitis B surface antigen would
identify hepatitis B disease.

However, viral hepatitis is

usually associated with fever, at least initially.

But of

the B cases of toxic jaundice in the first outbreak

described, none of the victims gave a history of fever.

In the second outbreak, only four of the 18 victims had
given a history of fever when examined by their doctors

and fever was recorded in only one cane on admission to

hospital.
50

In isolated cases, it would obviously be difficult to

differentiate between viral hepatitis and toxic hepatitis

from chemical exposure.

Diagnosis of toxic hepatitis would

arise from a high index of suspicion.

Company doctors

would find it useful periodically to do a simple analysis
of the statistics on their patients.

This would help in

the detection and prevention of occupational disease,
which would be missed unless doctors became more aware of
a possible occupational aetiology in some of the diseases
which they see (Medical' Journal of Malaysia, March 1983:

31-4).

51

CHAPTER 7

CONCLUSION

This report has attempted to make a case for the need to
remove chloroform from all preparations containing this
compound currently being sold on the market.

In so doing,

it has examined studies on the compound as well as

literature, legislation and action taken by health

authorities on the compound, worldwide.

Chloroform has been shown to be a highly potent and highly

dangerous anaesthetic.

Given the availability of

alternative and equally effective agents on the market

today, it is clear that this compound should not be in use.

It would be worthwhile to quote once more the dangers of
this compound according to Vickers ’ Drugs in Anaesthetic

Practice: 'The major disadvantage of chloroform is its effect
on the liver, as severe liver damage can follow short
exposures.

In so-called delayed chloroform poisoning the

effects of chloroform administration appear 24-48 hours

after administration.

There is centrilobular necrosis

which, in severe cases, may become massive.

This form of

liver damage is said to be more likely to occur in starved,

dehydrated and toxic patients or in those repeatedly exposed
to chloroform. 1 (Vickers, et al, 1979: 140)

52

Children are more susceptible to the adverse effects of

this compound because they are repeatedly exposed to
preparations containing this compound.

Many of the

advertisements for products containing chloroform, for
example, cough mixtures, are directly aimed at children.

Drug companies cannot be allowed to promote medicines
containing such compound.

This can lead to irrational

use of the medicines.

CAP strongly urges the Ministry of Health to immediately
recall all preparations containing this compound from the

market and ban the use of chloroform in such preparations

in the future, for the safety and health of Malaysian
consumers.

53

REFERENCES

1.

Ahmadizadeh, M, et al, ’Sex and Strain Differences
in Mouse Kidney: Bowman’s Capsule Morphology and
Susceptibility to Chloroform’, Toxicology Letters,
1984 Vol 20: 161-72.

2.

Ang Mamimili , April 1978 Vol VII No 4: 66.

3.

Berita Farmasi, ’Society News’, February 1977 Vol 4
No 2: 27.

4.

Consolidated List of Products Whose Consumption
and/or Sale Have Been Banned, Withdrawn, Severely
Restricted or Not Approved by Governments, Prepared
by the United Nations Secretariat in response to
General Assembly resolution 37/137, 30 December 1983.

5.

Department of Health and Social Security, UK, The
Medicines (Chloroform Prohibition) Order SI 1979:
382, cf WHO DIB, ’Chloroform and Carcinogenesis’
Oct-Dec 1979: 5-6.

6.

Eschenbrenner, A B, Miller, E, ’Induction of
hepatomas in mice by repeated oral administration of
chloroform, with observations on sex differences’,
Journal of the National Cancer Institute, 1945 Vol 5:
251-5, cf Public Citizen.

7.

Federal Register, 9 Feb 1973, cf Public Citizen.

8.

Goh, K T, Lee, L T, Tan, K T, and Kwok, S F, ’Toxic
Jaundice from Occupational Exposure to Chloroform’ ,
Medical Journal of Malaysia, March 1983 Vol 38
No 1: 31-4.

9.

IARC Monographs on the Evaluation of Carcinogenic
Risk of Chemicals to Man, Lyon: 1972 Vol 1: 61-5, cf
Public Citizen.

10-.

Journal of the American tMedical Association, 1973
Vol 224: 621, cf Public Citizen.

54

11.

Martindale, The Extra Pharmacopoeia, 28th edition,
1982.

12.

National Cancer Institute ’Report on the Carcino­
genesis Bioassay of Chloroform’, 1976, cf WHO DIB
’Potential Carcinogenicity of Chloroform’, October
1976: 13.

13.

National Institute for Occupational Safety and Health,
Rockville, USA, cf The Medical Journal of Australia,
4 Feb 1984: 184.

14.

Parish, Peter, Medicines: A Guide for Everybody,
Hammonds Worth, Middlesex: Penguin 1976: 314.

15.

Pohl, L R, et al, ’Strain and Sex Differences in
Chloroform - Induced Nephrotoxicity, Drug Metabolism
and Disposition’, The American Society of Pharmacology
and Experimental Therapeutics 1984 Vol 12 No 3: 304-8.

16.

Public Citizen, ’Dr Sidney Wolfe’s letter to the
Commissioner of FDA, Dr Alexander M Schmidt’, Health
Research Group, 30 December 1975.

17.

UICC Monograph Series 1967 Vol 1: 135, cf Public
Ci ti zen.

18.

Vickers, M D, Wood-Smith, F G, Stewart, H C,
Drugs in Anaesthetic Practice 5th ed, 1979: 140.

19.

WHO Drug Information Bulletin:

a)

’Potential Carcinogenicity of Chloroform’,
October 1976: 13.

b)

’Regulatory Decisions Taken in 1976’, JanuaryMarch 1977: 19.

c)

’Other Recent Regulatory Decisions’, JanuaryMarch 1979: 19.

d)

’Other Recent Regulatory Decisions’, April-June
1984: 25.

55

APPENDIX 1

DOSAGE INSTRUCTIONS FOR WOODS' GREAT PEPPERMINT
CURE

APPENDIX 2

DOSAGE INSTRUCTIONS FOR BOON'S COUGH REMEDY

APPENDIX 3

DOSAGE INSTRUCTIONS FOR BREACOL COUGH SYRUP

APPENDIX 4

PACKAGE INSERT FOR KWAN LOONG MEDICATED OIL

APPENDIX 5

PACKAGE INSERT FOR TIGER OIL

A RJ -ft °

«« »

» A 41 > iM. ’ MiR



, n* ,

♦ %&££. ’ #i&’S

’ &£±&$ = jiF^WSA^ ■>

TIGER OIL
(FOR EXTERNAL USE ONLY)
. TIGER OIL is manufactured by the most up-to-date pharmaceutical processes. Its produc­
tion is carefully controlled at all stages by skilled pharmacists and chemists to give a product
of the highest quality.
Only ingredients of proven efficacy, highest purity and quality are used. This preparation
is a time-tested and effective household remedy for the Symptomatic relief of:
HEADACHE, STOMACHACHE. COLDS. COUGHS. GIDDINESS. OVERWORK. MENTAL
r>.ne^-r.^I,RER^ESS- ,N?.ECT BITES. TRAVELLING SICKNESS. RHEUMATISM.
DIRECTIONS: Where applicable, rub gently on affected parts with a few drops of TIGER OIL.
Otherwise use as an inhalant.

Made under licence from
HAW PAR BROTHERS INTERNATIONAL LTD.

MINYAK HARIMAU
(UNTOK DI-SAPUKAN DI-LUAR SAHAJA)
MINYAK HARIMAU, di-buat menurut peroses pembuat obat yang paling terbaharu sekali.
Pengeluaran-nya di-awasi dengan teliti dari segala segi oleh ahli2 kimia dan farmasi yang bijak
untok menghasilkan ketinggian mutu-nya.
Hanya ramuan2 yang berseh dan tinggi mutu-nya dan telah lama tahan uji sahaja yang
telah di-gunakan.
Ada-lah persediaan dan cbat yang sangat mujarab di-simpan di-rumah bag! melegakan
dengan segera sakitZ:
PENING KEPALA, SAKIT PERUT, SALSEMA. BATOK, PITAM, TERLALU BANYAK
BEKERJA, LETEH OTAK, DI-GICIT SERANGGA, MABOK DI-PERJALANAN. BISA2
TULANG.
. .
.
PERATORAN-NYA: Chara menggunakan-nya sapu di-tempat yang sakit dengan beberapa
titik MINYAK HARIMAU. Jika tidak. boleh juga di-buat sa-bagai obat chium.

Di-perbuat daripada
HAW PAR BORTHERS INTERNATIONAL LTD.

APPENDIX 6

PACKAGE INSERT FOR GOLD FISH MEDICATED OIL

TRADE

fi. ft ft
'F
A
* £f. A A &

&

£

U

*

i£ A
X

A tf

it +

&

if
a

5M Ht
ll£

&

U 46 m M ij it
jh <■
■4 « <
ft M r ’T *.

*ffl

M
/)

a
&
#

ft
it

*

*
IX

GOLDFISH MEDICATED OIL
LAQINO

MAOHANDA

NO

LANGU

NA 'OOLDraB-

HWONG LAG ANO ’ OOCDftSH MEDICATED O<'

Drugs and the Third World:

Chloroform
Sale and Hazards
— a Malaysian Study
Chloroform is a highly potent and dangerous anaesthetic which can
cause damage to the liver as well as the kidneys. It is a proven car­
cinogen as well.
Many countries have banned the use of chloroform. However it
continues to be found in many products marketed in Malaysia.
These include medicinal preparations such as cough mixtures.

This study highlights the dangers of continued exposure to chloro­
form, and calls for a tightening of local health regulations regarding
the compound.

The Consumers* Association of Penang (CAP) is a non-profit making organisa­
tion which fights for the rights and interests of Malaysian consumers through

research, educational and representational activities.
The issues it takes up include the fulfilment of basic needs (food, nutrition,
health, housing, transport, etc.), food and product safety, environmental po u
tion and problems, the rational use of resources, specific problems o women,

and business malpractices.
This is part of a series of CAP Reports aimed at providing the Pu^ nJ^Mhis
results of some of the important areas of CAP’s activities, t is °P
towards
series will generate public interest and awareness, and help to contr
a better life for Malaysians.
of Penang 1986

Copyright ©Consumers’ Assochuion 9950 - 24-7

Position: 3756 (2 views)